B-cell depleting therapies have come a long way since rituximab's FDA approval for rheumatoid arthritis 20 years ago. Today, next-generation monoclonal antibodies like obinutuzumab and CAR T-cell therapies are generating real excitement — with some patients achieving striking, drug-free remissions in conditions like lupus and systemic sclerosis. But experts are urging caution, noting that enthusiasm must be tempered by a still-incomplete safety profile and significant structural barriers to widespread use.

The recent halt of Novartis and Bristol Myers Squibb CAR T-cell trials — following three reported deaths — has brought safety concerns into sharp focus. Experts note that with deeper B-cell depletion comes greater infection risk, and with only around 200 cellular therapy trials completed so far, the field is still too early to fully assess long-term risks like malignancy or mortality. Patient selection, access disparities, and the complexity of manufacturing also remain major hurdles.

Key Takeaways:

• Obinutuzumab (FDA-approved for lupus nephritis in Oct. 2025) showed a 76.7% SRI-4 response rate vs. 53.5% for placebo in the ALLEGORY trial
• CAR T-cell therapy offers the deepest B-cell depletion but carries the highest risk; monoclonal antibodies like inebilizumab and ianalumab may offer a middle ground
• Experts caution against using the word "cure" — sustained treatment-free remission is a more realistic near-term goal for select patients

Why it matters: As the autoimmune treatment landscape rapidly expands, clinicians face the challenge of matching the right therapy to the right patient — balancing remarkable efficacy potential against real and still-emerging safety risks.